INDSWFTLTD.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 17:44):

Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India...

Stats
本日の出来高	6 450.00
平均出来高	261 761
時価総額	1.25B
EPS	INR0 ( 2024-02-14 )
次の収益日	( INR0 ) 2024-05-14
Last Dividend	INR0.400 ( 2011-09-21 )
Next Dividend	INR0 ( N/A )
P/E	4.17
ATR14	INR0 (0.00%)

Ind-Swift Limited 相関

10 最も正の相関
GUJRAFFIA.NS	0.898
SABTN.NS	0.881
ROLLT.NS	0.876
HYBRIDFIN.NS	0.876
MOREPENLAB.NS	0.874
TGBHOTELS.NS	0.874
21STCENMGM.NS	0.871
MAXIND.NS	0.869
CONFIPET.NS	0.865
NECLIFE.NS	0.865

10 最も負の相関
JINDCOT.NS	-0.883
ISMTLTD.NS	-0.861
BLUESTARCO.NS	-0.852
RAJRILTD.NS	-0.844
KAYNES.NS	-0.838
GNA.NS	-0.834
ROTO.NS	-0.827
JINDALSAW.NS	-0.823
DFMFOODS.NS	-0.823
KPRMILL.NS	-0.823

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Ind-Swift Limited 財務諸表

Annual	2022
収益:	INR4.11B
総利益:	INR1.93B (46.94 %)
EPS:	INR4.81

FY	2022
収益:	INR4.11B
総利益:	INR1.93B (46.94 %)
EPS:	INR4.81

FY	2022
収益:	INR3.98B
総利益:	INR1.62B (40.63 %)
EPS:	INR-3.70

FY	2021
収益:	INR3.56B
総利益:	INR1.70B (47.61 %)
EPS:	INR-5.50

Financial Reports:

No articles found.

Ind-Swift Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ind-Swift Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0.656 - low (50.00%) | Divividend Growth Potential Score: 2.60 - No dividend growth expected in the near future

Information

First Dividend	INR0.400	2005-09-22
Last Dividend	INR0.400	2011-09-21
Next Dividend	INR0	N/A
Payout Date	2011-10-26
Next Payout Date	N/A
# dividends	7	--
Total Paid Out	INR2.80	--
Avg. Dividend % Per Year	0.00%	--
Score	1.06	--
Div. Sustainability Score	0.656
Div.Growth Potential Score	2.60
Div. Directional Score	1.628	--

Next Divdend (Est)
(2024-06-27)

INR0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

1.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR0	0.00%
2020	INR0	0.00%
2021	INR0	0.00%
2022	INR0	0.00%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SUNDARMHLD.NS	Dividend Junior	2023-07-03	Annually	7	1.35%
NATIONALUM.NS	Dividend Knight	2023-09-15	Semi-Annually	26	4.12%
HLEGLAS.NS	Dividend Junior	2023-09-21	Annually	4	0.19%
CANTABIL.NS	Dividend Junior	2023-09-15	Annually	5	0.63%
RITES.NS	Dividend Knight	2023-09-08	Quarterly	7	3.95%
LAMBODHARA.NS	Dividend Junior	2023-09-14	Annually	10	0.87%
FORCEMOT.NS	Dividend Junior	2023-09-21	Annually	6	0.45%
APLAPOLLO.NS	Ex Dividend Junior	2023-09-01	Sporadic	13	0.07%
TATVA.NS	Dividend Junior	2023-09-08	Annually	3	0.04%
NUCLEUS.NS	Dividend Junior	2023-07-07	Annually	22	1.41%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0630	1.500	8.74	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	-0.0420	1.500	-1.578	-2.37	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	0.470	1.000	-0.937	-0.937	[3 - 30]
operatingCashFlowPerShareTTM	18.32	2.00	3.89	7.79	[0 - 30]
freeCashFlowPerShareTTM	17.03	2.00	1.487	2.97	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.377	1.000	7.06	7.06	[0.2 - 0.8]
operatingProfitMarginTTM	0.0625	1.000	-0.749	-0.749	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				0.656

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	4.26	1.000	9.67	0	[1 - 100]
returnOnEquityTTM	-0.0420	2.50	-1.014	-2.37	[0.1 - 1.5]
freeCashFlowPerShareTTM	17.03	2.00	4.32	2.97	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	18.32	2.00	3.89	7.79	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	0.0185	1.500	-3.21	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.210	1.000	7.25	0	[0.1 - 0.5]
Total Score				2.60

Ind-Swift Limited

Ind-Swift Limited manufactures and sells pharmaceutical formulations, finished goods dosages, active pharmaceutical ingredients, and herbal products in India. It offers medicines for various therapeutic segments, such as ENT, dentistry, anti-infective, cardio-diabetic, and orthopedic therapies under the Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin, and Stemin Forte names; gynecology, pediatrics, dermatology, and GP under the Anin, Suprox, Cozy, Distone, and Oliade name; and antibiotic, anti-cold, nutraceuticals, anti-diarrheal, anti-malarial, anti-depressants, cardiology, diabetology, neurology, and oncology. The company also provides contract research and manufacturing services. It serves government dispensaries, doctors, and hospitals through retailers, stockists, and carrying and forwarding channels. The company exports its products to approximately 50 countries. Ind-Swift Limited was founded in 1983 and is based in Chandigarh, India.